255 related articles for article (PubMed ID: 9076469)
1. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.
Palmberg C; Koivisto P; Hyytinen E; Isola J; Visakorpi T; Kallioniemi OP; Tammela T
Eur Urol; 1997; 31(2):216-9. PubMed ID: 9076469
[TBL] [Abstract][Full Text] [Related]
2. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide.
Haapala K; Hyytinen ER; Roiha M; Laurila M; Rantala I; Helin HJ; Koivisto PA
Lab Invest; 2001 Dec; 81(12):1647-51. PubMed ID: 11742035
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
Koivisto P; Kononen J; Palmberg C; Tammela T; Hyytinen E; Isola J; Trapman J; Cleutjens K; Noordzij A; Visakorpi T; Kallioniemi OP
Cancer Res; 1997 Jan; 57(2):314-9. PubMed ID: 9000575
[TBL] [Abstract][Full Text] [Related]
6. Bicalutamide dosages used in the treatment of prostate cancer.
Kolvenbag GJ; Nash A
Prostate; 1999 Apr; 39(1):47-53. PubMed ID: 10221266
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
[TBL] [Abstract][Full Text] [Related]
8. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.
Verhelst J; Denis L; Van Vliet P; Van Poppel H; Braeckman J; Van Cangh P; Mattelaer J; D'Hulster D; Mahler C
Clin Endocrinol (Oxf); 1994 Oct; 41(4):525-30. PubMed ID: 7525125
[TBL] [Abstract][Full Text] [Related]
9. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
10. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.
Blackledge GR; Cockshott ID; Furr BJ
Eur Urol; 1997; 31 Suppl 2():30-9. PubMed ID: 9074908
[TBL] [Abstract][Full Text] [Related]
11. The development of Casodex (bicalutamide): preclinical studies.
Furr BJ
Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
13. Clinical progress with a new antiandrogen, Casodex (bicalutamide).
Blackledge GR
Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470
[TBL] [Abstract][Full Text] [Related]
14. Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer.
Edwards J; Krishna NS; Mukherjee R; Watters AD; Underwood MA; Bartlett JM
BJU Int; 2001 Oct; 88(6):633-7. PubMed ID: 11678763
[TBL] [Abstract][Full Text] [Related]
15. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
16. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
Tyrrell CJ; Kaisary AV; Iversen P; Anderson JB; Baert L; Tammela T; Chamberlain M; Webster A; Blackledge G
Eur Urol; 1998; 33(5):447-56. PubMed ID: 9643663
[TBL] [Abstract][Full Text] [Related]
17. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
18. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.
Hobisch A; Hoffmann J; Lambrinidis L; Eder IE; Bartsch G; Klocker H; Culig Z
Urol Int; 2000; 65(2):73-9. PubMed ID: 11025427
[TBL] [Abstract][Full Text] [Related]
19. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
20. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
